Berlin

• An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr … Ended recruitment
  2024-517959-12-00 9 2024-04-11 Relapsed/refractory B cell precursor acute lymphoblastic leukemia
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended recruitment
  2023-506195-27-00 5 2024-04-05 non-segmental vitiligo
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati … Ended recruitment
  2023-504124-26-00 5 2024-04-04 Chronic Kidney Disease and High Proteinuria
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil … Ended recruitment
  2023-506029-12-00 5 2024-04-03 Migraine
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either … Ended recruitment
  2023-503357-35-00 4 2024-03-20 Non-small Cell Lung Cancer (NSCLC)
• Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihis … Ended recruitment
  2023-505446-25-00 9 2024-03-20 Chronic Spontaneous Urticaria
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended recruitment
  2023-504827-17-00 5 2024-03-18 Chronic migraine
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended recruitment
  2023-504839-40-00 5 2024-03-18 Episodic Migraine
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended recruitment
  2023-504993-40-00 5 2024-02-14 Human immunodeficiency virus (HIV)
• Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended recruitment
  2023-505844-21-00 3 2024-02-14 juvenile idiopathic arthritis
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-dai … Ended recruitment
  2023-503531-18-00 6 2024-02-13 Prophylaxis of transplant rejection in adult kidney allograft recipien
• Effects of BBP-418 (ribitol) in Patients with LGMD2I Ended recruitment
  2023-503379-33-01 5 2024-02-12 Limb Girdle Muscular Dystrophy 2I/R9
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended recruitment
  2022-503040-41-00 4 2024-02-09 PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study of RZ358 in Patients with Congenital Hyperin … Ended recruitment
  2023-503240-13-00 5 2024-01-30 Hypoglycemia associated with congenital hyperinsulinism
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505120-59-00 5 2023-12-19 Moderate to Severe Plaque Psoriasis

Showing 1,009–1,032 of 1,776 trials